June 24, 2020 / 8:19 PM / 10 days ago

BRIEF-Insmed - Positive Results From Phase 2 Willow Study Of Brensocatib

June 24 (Reuters) - Insmed Inc:

* POSITIVE RESULTS FROM PHASE 2 WILLOW STUDY OF BRENSOCATIB IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS PRESENTED AT ATS VIRTUAL CLINICAL TRIALS SESSION

* INSMED INC - BRENSOCATIB SHOWN TO REDUCE TIME TO FIRST PULMONARY EXACERBATION AND REDUCE RATE OF EXACERBATIONS VERSUS PLACEBO

* INSMED INC - NEW DATA DEMONSTRATE RELATIONSHIP BETWEEN NEUTROPHIL ELASTASE REDUCTION AND RISK OF EXACERBATION IN PATIENTS TREATED WITH BRENSOCATIB

* INSMED - WILLOW STUDY MET ITS PRIMARY ENDPOINT

* INSMED INC - BRENSOCATIB WAS GENERALLY WELL-TOLERATED IN STUDY

* INSMED - TREATMENT WITH BRENSOCATIB 10 MG RESULTED IN SIGNIFICANT REDUCTION IN RATE OF PULMONARY EXACERBATIONS VERSUS PLACEBO

* INSMED - PLANS TO INITIATE PHASE 3 PROGRAM FOR BRENSOCATIB IN BRONCHIECTASIS IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below